Andrew K. Balo, EVP, Reg. Strategy, Clinical at DEXCOM INC (DXCM), sold 6,490 shares at $61.23 ($397K) on 2017-12-11, disclosed to the SEC on 2017-12-13.
Seasonal sale ($397k) by EVP, Reg. Strategy, Clinical — this insider has traded DXCM in December in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $61.23 | 3,245 | $199K | 50.0% |
| 2 | $61.23 | 3,245 | $199K | 50.0% |
| Total | $61.23 avg | 6,490 | $397K | 100% |
| Filing → |
| DXCM | SELL | 2021-07-08 | $2.4M | — | Filing → |
| DXCM | SELL | 2021-06-07 | $897K | — | Filing → |
| DXCM | SELL | 2021-03-12 | $4.0M | — | Filing → |